Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Common Equity (2016 - 2025)

Historic Common Equity for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $22.0 million.

  • Lineage Cell Therapeutics' Common Equity fell 6598.45% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 6598.45%. This contributed to the annual value of $78.4 million for FY2024, which is 2359.23% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Common Equity of $22.0 million as of Q3 2025, which was down 6598.45% from $48.4 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Common Equity high stood at $124.7 million for Q2 2021, and its period low was $22.0 million during Q3 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' median Common Equity value was $73.3 million (recorded in 2022), while the average stood at $77.6 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Common Equity soared by 3226.39% in 2021, and later plummeted by 6598.45% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Common Equity (Quarter) stood at $92.2 million in 2021, then fell by 20.47% to $73.3 million in 2022, then fell by 13.53% to $63.4 million in 2023, then rose by 23.59% to $78.4 million in 2024, then crashed by 71.88% to $22.0 million in 2025.
  • Its Common Equity was $22.0 million in Q3 2025, compared to $48.4 million in Q2 2025 and $79.0 million in Q1 2025.